Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

Abstract Number: 0340 • ACR Convergence 2023
Rheumatology Patients’ Experiences of a Nationwide Transition to an Adalimumab Biosimilar: A Cross-Sectional Study
Chiara Gasteiger¹, Maria Lobo², Robin Stanley¹, Lun Shen Wong¹, Rachel Murdoch¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand
Background/Purpose: Patients are frequently transitioned to biosimilars to reduce the cost burden of biologics. Brand changes can be daunting for patients who have concerns about…
Abstract Number: 1941 • ACR Convergence 2023
Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations
Eduardo Martin-Nares¹, Beatriz E. Sánchez-Hernández², Peter Grayson³, Jose Crispin¹, Daniel Montante-Montes de Oca², Andrea Hinojosa-Azaola¹, Gabriela Hernandez-Molina¹, Elia Apodaca⁴, Emma M. Groarke⁵, Jesús Delgado-de la Mora², Silvia Méndez-Flores⁶, Armando Gamboa-Domínguez², Bhavisha Patel⁷ and Marcela Ferrada⁸, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁴Department of Oncology and Hematology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD, ⁶Department of Dermatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷National Institutes of Health, Beltsville, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited information on VEXAS syndrome in the Latin-American population. We aimed to identify UBA1 mutations causing VEXAS syndrome in Mexican patients presenting…
Abstract Number: 0713 • ACR Convergence 2023
IgG4-Related Disease as a Potencial Etiology of Idiopathic Constrictive Pericarditis
Edwin Ulises Cortez-Domínguez¹, Gabriela Hernandez-Molina¹, Norma Ofelia Uribe-Uribe², María J Lizardo-Thiebaud² and Eduardo Martin-Nares¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Constrictive pericarditis (CP) is a type of diastolic heart failure characterized by impaired cardiac filling due to the presence of an inelastic pericardium. Histologically,…
Abstract Number: 1942 • ACR Convergence 2023
Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases
Carmen Lasa¹, Joy Selene Osorio², David Martínez-Lopez³, Carmen Alvarez Reguera⁴, Virginia Portilla⁵, Jose Cifrian⁶, Ivan Ferraz Amaro⁷ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Sierrallana, Torrelavega, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁶Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: Patients with rheumatic immune-mediated inflammatory diseases (rheumatic-IMID) with latent tuberculosis infection (LTBI) requiring biologic therapy (BT) are at anincreased risk of developing active tuberculosis…
Abstract Number: 1004 • ACR Convergence 2023
Telerheumatology Shared-Care Model: Leveraging the Expertise of an ACPAC-Trained Extended Role Practitioner (ERP) in Rural-Remote Ontario
Amanda Steiman¹, Taucha Inrig², Katie Lundon³, Jocelyne Murdoch⁴ and Rachel Shupak⁵, ¹Sinai Health System, Toronto, ON, Canada, ²St. Michael's Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Arthritis Society, Toronto, ON, Canada, ⁵St. Michael's Hospital/University of Toronto, Toronto, ON, Canada
Background/Purpose: A shortage of Rheumatologists has led to gaps in inflammatory arthritis (IA) care in Canada. Amplified in rural-remote communities, the number of Rheumatologists practicing…
Abstract Number: 2520 • ACR Convergence 2023
Identification of Clinical Phenotypes in Sarcoidosis Using a Cluster Analysis
Carmen Lasa¹, Raul Fernandez-Ramon², Jorge Javier Gaitán², Jose Luis Martin-Varillas³, Rosalía Demetrio², Ivan Ferraz Amaro⁴, Santos Castañeda⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Hospital de la Princesa, Madrid, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Sarcoidosis is a disease with heterogeneous clinical presentation and course. The objective of this study is the identification of clinical phenotypes using cluster analysis.…
Abstract Number: 1005 • ACR Convergence 2023
Telemedicine for Rheumatology Care: A Randomized, Single-Blind, Parallel Group, Noninferiority Trial
Lesley E. Jackson¹, Jinoos Yazdany², Kiara Aaron¹, Sarah Goglin³, Mary Margaretten², David Chae⁴, Jeffrey Curtis¹, Diana Paez⁵, Gary Cutter¹, Kenneth Saag¹ and Maria I. ("Maio") Danila⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of California San Francisco, San Francisco, CA, ³University of California San Francisco, Burlingame, CA, ⁴Tulane University School of Public Health & Tropical Medicine, New Orleans, LA, ⁵University of California San Francisco, Department of Medicine/Rheumatology, San Francisco, CA, ⁶University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: In the wake of the COVID-19 pandemic, telemedicine rapidly became standard of care for people with rheumatic diseases. Observational data on effectiveness and acceptability…
Abstract Number: 1061 • ACR Convergence 2023
Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology
Chani-mi Lee¹, Margaret Wang², Aarthi Rajkumar¹, Cassandra Calabrese³ and Leonard Calabrese³, ¹University Hospital, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known…
Abstract Number: 1071 • ACR Convergence 2023
No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)
Madeline O'Sullivan¹, Grant Cannon¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel⁴, Jessica A Walsh⁵, Punyasha Roul⁶, Bryant England⁶, Ted R Mikuls⁷, Joshua Baker⁸ and Tawnie Braaten⁴, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴University of Utah, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) are used to treat multiple cancers with increasing frequency and have led to improved survival. However, there is limited data…
Abstract Number: 1079 • ACR Convergence 2023
Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements
Tawnie Braaten¹, Selene Rubino¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel¹, Jessica A Walsh⁴, Shardool Patel⁵ and Grant Cannon⁵, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Immune Checkpoint Inhibitor (ICI)-induced myositis (ICI-myositis) is a rare, but potentially fatal complication of ICI therapy.Electronic health record (EHR) databases are essential to accrue…
Abstract Number: 1149 • ACR Convergence 2023
Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series
Tessalyn Morrison¹, Taylor Lakusta-Wong¹, Chantal Roy-Hewitson¹, Jeanne Gosselin² and Alana Nevares³, ¹University of Vermont, Burlington, VT, ²University of Vermont Medical Center, Waterbury, VT, ³University of Vermont, Essex Junction, VT
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by non-necrotizing granuloma formation affecting the lung, lymphatics, heart, skin, eye, kidney, and, in neurosarcoidosis, the nervous…
Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Greta Mastrangelo¹, Ellen Go², Paul Tsoukas², Hua Lu³, Amy Xu², Arthur Hoi Hin Cheng² and Rae Yeung⁴, ¹The Hospital of Sick Children,Department of Paediatrics, University of Toronto, Division of Rheumatology, Toronto, ON, Canada, ²The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…
Abstract Number: 033 • 2023 Pediatric Rheumatology Symposium
Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C)
Lyndsey Cole, Marsha Anderson, Heather Heizer, Michelle Hite, Christina Osborne, Samuel Dominguez and Pei-Ni Jone, University of Colorado School of Medicine, Denver, CO
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory illness associated with SARS-CoV-2 infection and has overlapping features with Kawasaki Disease (KD). The objective…
Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium
Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey
Daniel Ibanez¹, Bianca Lang², Ali Yalcindag³, Linda Wagner-Weiner⁴, Julia Shalen⁵, Kenneth Schikler⁶, Shoghik Akoghlanian⁷, Hulya Bukulmez⁸, Kristen Hayward⁹, Sivia Lapidus¹⁰, Andrea Ramirez¹¹, Robert Sundel¹, Cagri Yildirim-Toruner¹² and CARRA Registry Investigators¹³, ¹Boston Children's Hospital, Boston, MA, ²Dalhousie University - Halifax, Halifax, NS, Canada, ³Hasbro Children's Hospital, Milton, MA, ⁴The University of Chicago, Chicago, IL, ⁵Johns Hopkins University, Baltimore, MD, ⁶University of Louisville School of Medicine Norton Children's Hospital, Louisville, KY, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ⁹Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA, ¹⁰Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹¹Baylor College of Medicine, Houston, TX, ¹²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ¹³CARRA, Washington, DC
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…
Abstract Number: 080 • 2023 Pediatric Rheumatology Symposium
Analysis of Proteasomal Activity – a Potential Diagnostic Tool for Proteasome-associated Autoinflammatory Syndromes (PRAAS)
Yoel Levinsky¹, Oded Scheuerman², Rotem Tal³, Gil Amarilyo³ and Liora Harel³, ¹Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ²Pediatric B department, Schneider children's medical center of Israel, Petach Tikva, Israel, ³Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel
Background/Purpose: Interferonopathies are a recently recognized group of genetic syndromes associated with uncontrolled activation of interferon. PRAAS (proteasome-associated autoinflammatory syndromes) is an interferonopathy caused by…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].